Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Fasenra is the brand name for benralizumab, an injected medicine that targets eosinophils, a type of white blood cell. It is an add-on maintenance treatment for severe eosinophilic asthma in people ages 6 and older. It is also approved for certain people with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome.
read more about fasenra ...Fasenra treats severe asthma with an eosinophilic pattern when added to other asthma treatment. It is also approved for adults with eosinophilic granulomatosis with polyangiitis. People ages 12 and older with hypereosinophilic syndrome can receive it when the condition meets the approved criteria.
Benralizumab attaches to a receptor on eosinophils. This leads the immune system to remove those cells from the blood and tissues. Lowering eosinophil levels can help control the conditions for which Fasenra is prescribed.
Fasenra is injected under the skin. The schedule differs by condition, and the asthma dose for children ages 6 to 11 also depends on body weight. A trained patient or caregiver can use the autoinjector when the treating clinician decides that home administration is appropriate.
Headache can occur during treatment. Other reported effects vary by condition and include sore throat, flu-like symptoms, or hypersensitivity reactions. Fasenra does not treat a sudden asthma attack, and severe allergic reactions require prompt medical care.
No. It is a maintenance treatment. Use the prescribed rescue medicine and follow the asthma action plan for sudden symptoms.
Eosinophils are white blood cells involved in immune responses. High levels can contribute to inflammation in certain diseases.
The schedule depends on the condition being treated. For asthma, injections are given every four weeks for the first three doses and then every eight weeks; the schedule for its other approved uses differs.
Some patients or caregivers can use the Fasenra Pen after training. A clinician decides whether home injection is appropriate.
Benralizumab (subcutaneous route) - Side effects & dosage. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/benralizumab-subcutaneous-route/description/drg-20406682. Date Accessed October 6, 2026.
Benralizumab Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a618002.html. Date Accessed October 6, 2026.
FASENRA HES Safety Information | Possible Side Effects & Important Warnings | FASENRA. AstraZeneca. https://www.fasenra.com/hypereosinophilic-syndrome/safety-information. Date Accessed October 6, 2026.
FASENRA- benralizumab injection, solution. DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da6aca1a-19ed-44a4-abb7-696c7d58b784. Date Accessed October 6, 2026.
Hypereosinophilic Syndrome (HES) Treatment | FASENRA. AstraZeneca. https://www.fasenra.com/hypereosinophilic-syndrome. Date Accessed October 6, 2026.